REVIEW
|
doi:10.20944/preprints202306.1811.v1
Subject:
Medicine And Pharmacology,
Dermatology
Keywords:
advanced melanoma; pembrolizumab; immunotherapy
Online: 26 June 2023 (12:07:15 CEST)
REVIEW
|
doi:10.20944/preprints202404.0944.v1
Subject:
Medicine And Pharmacology,
Immunology And Allergy
Keywords:
Immune checkpoint inhibitor; ipilimumab; pembrolizumab ;
Online: 16 April 2024 (03:30:17 CEST)
CASE REPORT
|
doi:10.20944/preprints202404.0157.v1
Subject:
Medicine And Pharmacology,
Oncology And Oncogenics
Keywords:
autoimmune encephalitis; checkpoint inhibitor; melanoma; pembrolizumab; adverse event
Online: 2 April 2024 (16:18:10 CEST)
CASE REPORT
|
doi:10.20944/preprints202104.0780.v1
Subject:
Medicine And Pharmacology,
Immunology And Allergy
Keywords:
Hereditary Leyomiomatosis and Renal Cell Cancer; Pembrolizumab; Axitinib
Online: 29 April 2021 (15:38:30 CEST)
ARTICLE
|
doi:10.20944/preprints202308.0506.v1
Subject:
Medicine And Pharmacology,
Oncology And Oncogenics
Keywords:
cemiplimab; pembrolizumab; immune checkpoint inhibitor; PD-1; cutaneous squamous cell carcinoma
Online: 7 August 2023 (10:37:53 CEST)
ARTICLE
|
doi:10.20944/preprints201809.0591.v1
Subject:
Medicine And Pharmacology,
Neuroscience And Neurology
Keywords:
adverse events; immune checkpoint inhibitor; myasthenia gravis; myopathy; neuropathy; nivolumab; pembrolizumab
Online: 29 September 2018 (11:28:00 CEST)
ARTICLE
|
doi:10.20944/preprints202404.1044.v1
Subject:
Medicine And Pharmacology,
Oncology And Oncogenics
Keywords:
Pembrolizumab; Non-small cell lung cancer; real-world data; Immunotherapy; observational study
Online: 16 April 2024 (14:06:32 CEST)
REVIEW
|
doi:10.20944/preprints202108.0037.v1
Subject:
Medicine And Pharmacology,
Oncology And Oncogenics
Keywords:
ovarian cancer; checkpoint inhibitors; ICIs; immunotherapy; PARP; avelumab; pembrolizumab; nivolumab; bevacizumab; platinum
Online: 2 August 2021 (13:01:35 CEST)
REVIEW
|
doi:10.20944/preprints201909.0140.v1
Subject:
Medicine And Pharmacology,
Oncology And Oncogenics
Keywords:
hepatocellular carcinoma; immune checkpoint inhibitors; HCC; pembrolizumab; nivolumab; immune microenvironment; targeted therapies
Online: 14 September 2019 (18:37:29 CEST)
ARTICLE
|
doi:10.20944/preprints202312.0497.v1
Subject:
Medicine And Pharmacology,
Oncology And Oncogenics
Keywords:
pembrolizumab; immunotherapy; temozolomide; durvalumab; brain tumor; cell migration; metastasis; glioblastoma; PD-1; PD-L1
Online: 7 December 2023 (16:57:26 CET)
ARTICLE
|
doi:10.20944/preprints202102.0068.v1
Subject:
Medicine And Pharmacology,
Immunology And Allergy
Keywords:
cost-effectiveness; pembrolizumab; etoposide-platinum; extensive-stage small-cell lung cancer; small cell lung cancer.
Online: 1 February 2021 (18:10:59 CET)
ARTICLE
|
doi:10.20944/preprints202111.0447.v1
Subject:
Medicine And Pharmacology,
Oncology And Oncogenics
Keywords:
Immunotherapy; immune-checkpoint inhibitor; response prediction; men and women; pembrolizumab; nivolumab; atezolizumab; ECOG; CRP; chemo-immunotherapy
Online: 24 November 2021 (09:02:46 CET)
CASE REPORT
|
doi:10.20944/preprints202005.0220.v1
Subject:
Medicine And Pharmacology,
Oncology And Oncogenics
Keywords:
checkpoint inhibitors; tuberculosis; non-small cell lung cancer (NSCLC); Anti-PD-1; toxicity management; immunotherapy; pembrolizumab
Online: 13 May 2020 (04:38:50 CEST)
REVIEW
|
doi:10.20944/preprints202307.0430.v1
Subject:
Medicine And Pharmacology,
Hematology
Keywords:
Hodgkin lymphoma; relapsed/refractory; brentuximab vedotin; checkpoint inhibitor; PD-1 inhibitor; nivolumab; pembrolizumab; autologous hematopoietic cell transplantation
Online: 6 July 2023 (11:44:13 CEST)
ARTICLE
|
doi:10.20944/preprints202105.0546.v1
Subject:
Medicine And Pharmacology,
Oncology And Oncogenics
Keywords:
triple negative breast cancer; Pembrolizumab; Atezolizumab; chemotherapy; anti-PD-L1; biomarkers; targeted therapies; development of novel drugs
Online: 24 May 2021 (09:23:50 CEST)
ARTICLE
|
doi:10.20944/preprints201808.0307.v3
Subject:
Medicine And Pharmacology,
Oncology And Oncogenics
Keywords:
Immune Checkpoint Inhibitors; anti-PD-1/PDL-1; anti-CTLA-4; gender; sex; Nivolumab; Pembrolizumab; Atezolizumab; Ipilimumab; Durvalumab
Online: 15 November 2018 (07:02:24 CET)
ARTICLE
|
doi:10.20944/preprints202406.0122.v1
Subject:
Medicine And Pharmacology,
Oncology And Oncogenics
Keywords:
Tissue agnostic drug development; Pembrolizumab; Microsatellite instability-high (MSI-H); Tumor mutational burden-high (TMB-H); Dostarlimab-gxly; Larotrectinib; Entrectinib; Neurotrophic tyrosine kinase (NTRK); Dabrafenib and trametinib; V-Raf Murine Sarcoma Viral Oncogene Homolog B V600E (BRAFV600E); Selpercatinib; Rearranged during transfection (RET); Precision oncology.
Online: 3 June 2024 (16:08:38 CEST)